Eli Lilly Alzheimer’s therapy approved in China

Eli Lilly (NYSE:LLY) announced Wednesday that China’s National Medical Products Administration (NMPA) has approved its Alzheimer’s treatment, Kisunla, making the country its fourth major market to approve the amyloid-targeting therapy.

Accordingly, Kisunla, an intravenous infusion also known as donanemab, will be available in